生物医药系列产品
数据
资源
版本对比
免费注册
预约演示
免费注册
BITT Announces NIH Award for Advancement of
Anti-CD40 Antibody
2023-08-31
·
BioSpace
免疫疗法
BOSTON--(BUSINESS WIRE)--
Boston Immune Technologies and Therapeutics, Inc.
(BITT), a clinical-stage biotechnology company developing novel
tumor necrosis factor superfamily receptor (TNFSR) antagonist antibodies
tumor necrosis factor superfamily receptor (TNFSR)
antagonist antibodies, announced today the award of funding from the
National Institutes of Health (NIH)
to support the preclinical development of BITT’s
CD40
antagonist antibody
. The award for Advancing BITT-101: A Novel Dominant CD40 Antagonist for Use in the Treatment of
Sjögren’s Syndrome
will help support steps toward an IND filing in 2024. “The NIH award will accelerate our path to the clinic,” said Russell LaMontagne, Co-Founder and Chief Executive Officer of BITT. “We believe our
anti-CD40 antibody
has novel properties that differentiate it from prior CD40 antagonists, and we anticipate it could have uses in multiple autoimmune indications beyond
Sjögren’s syndrome
.” In preclinical studies,
BITT antibodies
exhibited the ability to deplete B cells and inhibit IgG levels – including a unique ability to selectively deplete activated (
CD86
+) and younger B cells making early IgM antibodies. This selective action could result in more potent immunosuppressive function at the site of
inflammation
and reduce the risk of side effects that have limited the clinical development of earlier
CD40
antagonists. About
CD40
CD40
is co-stimulatory protein on antigen presenting cells (
CD154
+). The
CD40-CD40 ligand (CD40L)
pathway is a key co-stimulatory pathway for driving T cell-dependent B cell activation and humoral immune responses. This pathway has been implicated in the pathogenesis of several
autoimmune diseases
, including
autoimmune thyroiditis
,
type 1 diabetes
, Crohn’s disease,
inflammatory bowel disease
,
psoriasis
,
multiple sclerosis
,
rheumatoid arthritis
,
systemic lupus erythematosus
and
Sjögren’s syndrome
. About
Boston Immune Technologies and Therapeutics, Inc.
Boston Immune Technologies and Therapeutics, Inc.
(BITT) is a clinical-stage biotechnology company based in Boston, MA. BITT is developing a novel class of antagonist antibodies targeting TNF superfamily receptors for applications in
oncology
,
inflammation
,
autoimmunity
, and
infectious disease
based on the company’s DOMab platform. BITT is initiating clinical trials for
BIR2101
, its lead candidate, which is a monoclonal antibody that targets
tumor necrosis factor receptor 2 (TNFR2)
. BITT is also developing additional antibodies targeting TNF superfamily receptors for indications in
inflammation
,
oncology
and
infectious disease
including a
CD40 antagonist
that recently completed developability studies and is progressing toward an IND filing. Learn more at: .
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Boston Immune Technologies & Therapeutics, Inc.
National Institutes of Health
适应症
抗合成酶综合征
炎症
自身免疫性疾病
[+9]
靶点
TNFR
CD40
CD86
[+2]
药物
anti-CD40 antibody (Jiangsu hengrui)
Sofusa anti-TNF(Sorrento Therapeutics)
Antagonist-G
[+2]
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
来和芽仔聊天吧
热门报告
特应性皮炎深度解析:药物开发、专利分析与风险评估
智慧芽生物医药
2024年7月全球首批及特殊审评药物报告
智慧芽生物医药
GPRC5D靶点专利调研报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务